Melbourne, Australia, 10 February 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a US$5 million investment from Flu Lab. Flu Lab, a California-based organization founded to advance innovative approaches for the prevention and treatment of influenza, […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-02-10 08:01:272025-02-10 08:01:27ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051
Publication comes as the prevalence of respiratory infections continues to rise worldwide Melbourne, Australia, 28 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to minimize the impact of respiratory viral infections in at-risk populations, announces today the publication of an invited review of the preclinical and clinical development […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-01-28 03:25:282025-01-28 08:07:34ENA Respiratory Publishes Review of Development of Novel Intranasal Antiviral Host Defense Immune Enhancer INNA-051 in Antiviral Research
New intranasal formulation with significantly improved stability was well-tolerated and led to local activation of innate immune pathways in adults aged >60 S. Department of Defense (DOD) funded study extension into younger adults aged 18 – 45 will complete dosing in January Melbourne, Australia, 22 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-01-22 05:00:512025-01-22 08:18:42ENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults
When compared to placebo, prophylactic administration of INNA-051 was associated with significantly increased expression of multiple host defense genes and shorter duration of infection in influenza virus-infected individuals Data published in ERJ Open Research, a leading open access journal in respiratory medicine Melbourne, Australia, 18 December 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2024-12-18 07:26:472024-12-18 07:26:47ENA Respiratory Announces Peer-Reviewed Publication of First Time in Humans and Influenza Virus Challenge Studies with the Intranasal Innate Immunomodulator INNA-051
New US $3.13 million DOD contract extension to fund inclusion of younger adults in the ongoing Phase Ib study of INNA-051 nasal dry powder formulation and drug product optimization activities Melbourne, Australia, 5 September 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00innimodhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svginnimod2024-09-05 09:00:062024-10-22 10:10:58ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral
Advances a new formulation with improved stability in the clinic Single ascending dose phase successfully completed, multiple ascending dose phase underway Melbourne, Australia, 27 August 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00innimodhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svginnimod2024-08-27 09:00:072024-10-22 10:11:17ENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051
ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051
Melbourne, Australia, 10 February 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a US$5 million investment from Flu Lab. Flu Lab, a California-based organization founded to advance innovative approaches for the prevention and treatment of influenza, […]
ENA Respiratory Publishes Review of Development of Novel Intranasal Antiviral Host Defense Immune Enhancer INNA-051 in Antiviral Research
Publication comes as the prevalence of respiratory infections continues to rise worldwide Melbourne, Australia, 28 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to minimize the impact of respiratory viral infections in at-risk populations, announces today the publication of an invited review of the preclinical and clinical development […]
ENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults
New intranasal formulation with significantly improved stability was well-tolerated and led to local activation of innate immune pathways in adults aged >60 S. Department of Defense (DOD) funded study extension into younger adults aged 18 – 45 will complete dosing in January Melbourne, Australia, 22 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing […]
ENA Respiratory Announces Peer-Reviewed Publication of First Time in Humans and Influenza Virus Challenge Studies with the Intranasal Innate Immunomodulator INNA-051
When compared to placebo, prophylactic administration of INNA-051 was associated with significantly increased expression of multiple host defense genes and shorter duration of infection in influenza virus-infected individuals Data published in ERJ Open Research, a leading open access journal in respiratory medicine Melbourne, Australia, 18 December 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing […]
ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral
New US $3.13 million DOD contract extension to fund inclusion of younger adults in the ongoing Phase Ib study of INNA-051 nasal dry powder formulation and drug product optimization activities Melbourne, Australia, 5 September 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections […]
ENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051
Advances a new formulation with improved stability in the clinic Single ascending dose phase successfully completed, multiple ascending dose phase underway Melbourne, Australia, 27 August 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has […]